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DepressionAbstract Background: Anxiety and depression are mental health problems that result in reduced
health-related quality of life (HRQL), and increased mortality. Patients with COPD have a higher
risk of anxiety and depression compared to healthy individuals. Recent studies reported a signiﬁ-
cant relationship between the presence of anxiety and depression and the functional status of COPD
patients.
Objectives: To study the effect of treatment of anxiety and depression on the physiological status
in COPD patients.
Materials and methods: The study included 50 severe COPD patients with depression and/or
anxiety as evaluated and scored by Montgomery and Asberg Depression Rating Scale (MADRS)
and Hamilton Anxiety Rating (HAM-A) Scale. They were classiﬁed into 2 groups: group I included
25 patients who received antidepressant/anxiolytic therapy in addition to COPD treatment and
group II included 25 patients who received COPD treatment only. Modiﬁed Borg scale dyspnea
score, spirometry (vital capacity, forced vital capacity, forced expiratory volume in ﬁrst second
and forced expiratory ﬂow through 25–75% of expiration), arterial blood, MADRS and HAM-A
scale were assessed in all patients at the start of the study and after 3 months.
Results: Patients with severe COPD who were treated for depression and/or anxiety showed a
signiﬁcant improvement in MADRS, HAM-A and dyspnea scales, spirometeric parameters and
oxygenation. MADRS and HAM-A scale showed a signiﬁcant negative correlation to FEV1.
30 O.M. Momtaz et al.Conclusion: Treatment of depression and anxiety in COPD patients is recommended as it is
associated with a signiﬁcant improvement in pulmonary physiological status and HRQL. Further
studies on larger scales are recommended.
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Chronic obstructive pulmonary disease (COPD) is a leading
cause of disability and mortality. Disability, functional limita-
tions and decreased health related quality of life (HRQL) in
patients with COPD are correlated with objective physiologic
measures of disease severity [1–3]. However, a large proportion
of the variance in functional status and HRQL associated with
COPD are not explained by measures of pulmonary physiol-
ogy. Several studies reported a signiﬁcant relationship between
functional status of COPD patients and the presence of anxiety
and/or depression [1–11]. These psychological factors may play
an important role in determining the impact of COPD on
patient’s functional state. For example, anxiety in patients with
COPD has been associated with decreased HRQL, more severe
dyspnea, greater disability, and impaired functional status [4,5]
even after improvement in lung function abnormalities [6,7].
Moreover, depression and anxiety have been found to be
related to the disease characteristics of COPD, including chest
symptoms [8], forced vital capacity [9], and dyspnea [10,11].
Co-morbid depression and/or anxiety also increase the eco-
nomic burden of the disease where COPD patients with
depression and/or anxiety were found to have a higher rate
of exacerbation, hospitalization and relapse after discharge
compared with COPD patients without depression and/or anx-
iety [8]. Another study suggested that depression has a possible
causal effect on COPD exacerbations and hospitalizations [12].
Furthermore, recent data indicate that mortality risk is three
times greater in COPD patients who had depressive symptoms
in one series [13]. In this work, we evaluate the effect of treat-
ment of anxiety and depression on the physiological status in
severe COPD patients.
Patients and methods
This prospective study was carried out on 50 patients with
severe COPD. All patients had been admitted for ﬂare up of
COPD in El-Minia University Hospital and were fully evalu-
ated for our study after becoming stable. They were selected
after the diagnosis of depression and/or anxiety. COPD diag-
nosis and disease severity classiﬁcation were done according
to the Global Initiative of Chronic obstructive Lung Disease
(GOLD 2009) [14].
All patients were subjected to the following: (1) Full history
and examination. (2) Assessment of dyspnea score using
modiﬁed Borg scale [15], arterial blood gas (ABG) analysis, spi-
rometry with measuring vital capacity (VC), forced vital capac-
ity (FVC), forced expiratory volume in 1 s (FEV1), and forced
expiratory ﬂow through 25–75% of expiration (FEF25–75%)
after improvement in COPD exacerbation before discharge
and after 3 months. Spirometry was done according to the
American Thoracic Society standards [16] and spirometricvalues used in this report were calculated using normal refer-
ence values derived from Crapo and colleagues [17].
Depression was assessed by Montgomery and Asberg
Depression Rating Scale (MADRS) [18]. It is composed of
10 main items graded from 0 to 6. Cut-off scores have been
assessed as follows: 0–6 indicates the absence of depression
(or recovery in the setting of a clinical trial); 7–19: mild
depression; 20–34: moderate depression; and 35 and above:
severe depression. Anxiety was assessed by Hamilton Anxi-
ety (HAM-A) [19]. It is composed of 14 items graded from
0 (not present) to 4 (disabling). The total score ranges from
0 to 56. A total score of 18 or more means anxiety, 18–24:
mild anxiety, 25–29: moderate anxiety, 30 and above: severe
anxiety. Depression and anxiety were assessed after improve-
ment in COPD exacerbation before discharge and after
3 months.
Patients were divided into 2 groups: group I included 25
patients of stage III and IV COPD associated with anxiety
and/or depression and received antidepressant/anxiolytic
therapy for 3 months in addition to COPD treatment. Group
II included 25 age and sex matched patients of stage III and
IV COPD associated with anxiety and/or depression and
received COPD treatment only. They did not receive antide-
pressant/anxiolytic therapy. Baseline MADRS and HAM-A
scores were matched in both groups. A selective serotonin
reuptake inhibitor (SSRI); ﬂuoxetine in a ﬁxed dose of
20 mg/d was given to all patients of group I because of the
known safety of this group of antidepressants for COPD
patients and its considerable anxiolytic effect. All patients
were assessed at the start of the study and then monthly
for 3 months. Patients with one of the following items were
excluded: (1) Depression or anxiety under treatment. (2)
Depression or anxiety caused by neuropsychiatric or other
disorders. (3) COPD with other comorbidities that may cause
depression.Statistics
Descriptive statistics were computed for each of the variables
analyzed. Results were presented as mean ± SD. In order to
compare the different groups; the dependent- and indepen-
dent-samples t-test between two groups was used. Chi-squared
test was used for comparison between categorical variables.
Pearson correlation test was used for detecting the relation
of MADRS and HAM-A scores to PFTs. Multivariate analy-
ses were performed to identify association between MADRS
and HAM-A scores as well as spirometric parameters and
the following patient characteristics: age, smoking index, body
mass index and dyspnea scale. All statistical analyses were per-
formed using SPSS version 14.0 statistical software (SPSS Inc.,
Chicago, IL, USA). A probability value of p< 0.05 was used
to determine statistical signiﬁcance.
Table 1 Prevalence of anxiety and depression in COPD
patients.
Studied patients (Stage III and
IV COPD patients)
Number Percentage
Patients had both anxiety and depression 13 26
Patients had depression alone 32 64
Patients had anxiety alone 5 10
Total 50 100
Table 5 Dyspnea scale, spirometry and ABG at the start of
study and after 3 months in patients of group I.
Test variable At the start 3 months later p Value
Dyspnea scale 4.36 ± 0.99 3.68 ± 1.09 0.001
VC (L/s) 2.32 ± 0.66 2.39 ± 0.60 0.05
FVC (L/s) 2.08 ± 0.54 2.18 ± 0.55 0.01
FEV1 (L/s) 1.10 ± 0.49 1.20 ± 0.44 0.01
FEF25–75% 0.63 ± 0.39 0.71 ± 0.38 0.01
pH 7.37 ± 0.02 7.39 ± 0.03 0.5
PaCO2 (mm Hg) 54 ± 8 48 ± 6 0.4
PaO2 (mm Hg) 65 ± 7 79 ± 6 0.05
SaO2 (%) 91 ± 2 96 ± 2 0.03
VC: vital capacity, FVC: forced vital capacity, FEV1: forced
expiratory volume in 1 s, FEF25–75%: forced expiratory ﬂow
through 25–75% of expiration, PaO2: partial arterial oxygen pres-
sure, SaO2: arterial oxygen saturation.
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The present study included 50 patients with severe COPD
selected after diagnosis of depression and/or anxiety. They
included 33 males (17 in group I and 16 in group II) and 17
females (9 in group I and 8 in group II) with the mean age
of 63.52 ± 2.43. All patients were classiﬁed as stage III and
IV COPD at the start of the study. Prevalence of anxiety
and depression in the studied patients is shown in Table 1
where 32 patients had depression alone, 5 patients had anxiety
alone and 13 patients had both anxiety and depression. Base-
line MADRS and HAM-A scores in both groups were compa-
rable at the start of the study where there was an insigniﬁcant
difference between them in both groups (Table 2). Effect of
treatment with antidepressant/anxiolytic therapy on MADRS
and HAM-A scores in group I is shown in Table 3 where there
was a signiﬁcant reduction in both scores after 3 months of
regular therapy reﬂecting a signiﬁcant improvement in HRQL.
In group II there were no signiﬁcant changes in MADRS after
3 months of COPD treatment and HAM-A score signiﬁcantly
increased reﬂecting worsening of anxiety in this group at the
end of the study (Table 4). Dyspnea scale, oxygenation andTable 2 MADRS and HAM-A in group I and II at the start of th
Scale Score at the start of the study in group
MADRS (mean ± SD) 27.54 ± 3.34
HAM-A (mean ± SD) 24.45 ± 3.34
MADRS: Montgomery and Asberg Depression Rating Scale; HAM-A: A
Table 3 Effect of antidepressant/anxiolytic therapy on MADRS an
3 months.
Patient group I At the start of the study
MADRS (mean ± SD) 27.54 ± 3.34
HAM-A (mean ± SD) 24.45 ± 3.34
MADRS: Montgomery and Asberg Depression Rating Scale; HAM-A: H
Table 4 MADRS and HAM-A scores in group II at the start of th
Patient group II At the start of the study
MADRS (mean ± SD) 26.29 ± 3.82
HAM-A (mean ± SD) 23.9 ± 4.23
MADRS: Montgomery and Asberg Depression Rating Scale; HAM-A: Hspirometric parameters were signiﬁcantly improved in group
I patients who had received antidepressant/anxiolytic therapy
but not in the non-treated group II patients (Tables 5 and 6).
There was a signiﬁcant negative correlation between means
of MADRS and HAM-A scores and COPD severity assessed
by FEV1 (r: 0.61, p 0.001 for MADRS and r: 0.74,
p 0.001 for HAM-A scores).
Discussion
Anxiety and depression are common mental health problems
that result in reduced HRQL, and increased mortality [5–7].
Patients with COPD have a higher risk of comorbid diseases
such as anxiety and depression compared to healthye study.
I Score at the start of the study in group II p Value
26.29 ± 3.82 0.65
23.9 ± 4.23 0.08
nxiety was assessed by Hamilton Anxiety Rating Scale.
d HAM-A scores in group I at the start of the study and after
After 3 months p Value
9.54 ± 2.34 0.001
20.56 ± 2.34 0.01
amilton Anxiety Rating Scale.
e study and after 3 months.
After 3 months p Value
25.98 ± 2.56 0.65
28.35 ± 2.76 0.01
amilton Anxiety Rating Scale.
Table 6 Dyspnea scale, spirometry and ABG at the start of
study and after 3 months in patients of group II.
Test variable At the start 3 months later p Value
Dyspnea scale 4.50 ± 1.01 5.17 ± 0.99 0.001
VC (L/s) 2.10 ± 0.51 2.9 ± 0.42 0.5
FVC (L/s) 1.86 ± 0.44 1.83 ± 0.41 0.5
FEV1 (L/s) 1.06 ± 0.38 1.04 ± 0.29 0.8
FEF25–75% 0.61 ± 0.31 0.58 ± 0.24 0.2
pH 7.36 ± 0.03 7.37 ± 0.02 0.1
PaCO2 (mm Hg) 54 ± 4 56 ± 4 0.8
PaO2 (mm Hg) 68 ± 4 67 ± 3 0.7
SaO2 (%) 94 ± 2 93 ± 2 0.8
VC: vital capacity; FVC: forced vital capacity; FEV1: forced
expiratory volume in 1 s; FEF25–75%: forced expiratory ﬂow
through 25–75% of expiration; PaO2: partial arterial oxygen pres-
sure; SaO2: arterial oxygen saturation.
32 O.M. Momtaz et al.individuals [7–10]. The incidence of anxiety and depression
increased with increased severity of COPD [20]. Recent studies
reported a signiﬁcant relationship between functional status of
COPD patients and the presence of depression [5–8]. Indeed
co-morbid psychological outcomes such as depression and
anxiety have been associated with increased functional disabil-
ity and poorer predicted outcomes [21].
Although dyspnea may be partially attributed to the psy-
chological process, the depressed PFTs highlighted the negative
effect of depression and anxiety on the pathophysiological pro-
cess in COPD. This attracted our concern to study the effect of
treatment of depression and anxiety on pulmonary physiologi-
cal parameters in COPD patients.
The current study included 50 stage III and IV COPD
patients with depression and/or anxiety: 25 patients received
antidepressant/anxiolytic therapy in addition to COPD treat-
ment (group I) and 25 age and sex matched patients were given
COPD treatment only (group II). In group I patients who had
received antidepressant therapy, there was a signiﬁcant
improvement in both anxiety and depression after 3 months
of treatment as reﬂected by a signiﬁcant reduction in MADRS
(p< 0.001) and HAM-A scores (p< 0.01) at the end of the
study. In group II patients who had not received antidepres-
sant therapy, MADRS score was reduced after 3 months
though this reduction was not statistically signiﬁcant. HAM-
A score on the contrary showed signiﬁcant elevation after
3 months reﬂecting clinical deterioration of anxiety in non-
treated patients. This elevation in HAM-A score in group II
at the end of the study may be attributed to the poor response
to treatment which makes the patient more anxious in addition
to the physiological deterioration in patient’s functional status
with time.
In this study, we used spirometric, ABG values and modi-
ﬁed Borg scale dyspnea score as the physiological parameters
to estimate improvement in COPD status. Dyspnea scale is a
subjective method to detect improvement whereas spirometric
and ABG values are an objective method. Although improve-
ment in dyspnea score is an important marker of improved
quality of life, it may be affected by various medical and psy-
chological aspects not related to pulmonary functions. How-
ever, spirometric, ABG values which are objective
parameters are superior in detection of ‘‘physiological’’improvement in lung function and health status of COPD
patients.
In our study pulmonary physiological parameters, as mea-
sured by modiﬁed Borg scale dyspnea score, spirometric and
ABG values were assessed before and after treatment. Dyspnea
scale showed a signiﬁcant improvement in group I compared
to deterioration in group II after 3 months of therapy. There
was a signiﬁcant improvement in spirometric parameters in
group I patients after 3 months of the antidepressant therapy.
Also ABG values showed a signiﬁcant improvement in PaO2
and SaO2 in group I patients after 3 months of treatment.
However there was worsening of most of these parameters in
group II patients who had not received antidepressant therapy.
In addition, MADRS and HAM-A scores showed a signiﬁcant
negative correlation with FEV1 where lower scores of MAD-
RS and HAM which indicate improvement in depression and
anxiety were associated with higher FEV1 levels reﬂecting
improvement in COPD state. A signiﬁcant improvement in
PFTs along with dyspnea scale in group I indicates that
improvement in pulmonary physiological functions comes
hand in hand with improvement in depression and anxiety.
These results highlight the obvious relation of depression
and anxiety in the pathogenesis of worsening and improve-
ment in COPD status. This was in agreement with some results
which proved that better detection and treatment of depression
in patients with COPD may result in improved clinical out-
comes and health resource utilization [22]. It should be men-
tioned that variations of PFTs and modiﬁed Borg dyspnea
scale were avoided by assessment of these tools in all patients
in all situations in the basal conditions (after correction of any
reversible causes that could alter any of these tools). In addi-
tion, treatment guidelines of COPD were submitted to all
patients by monthly clinical assessment. Thus improvement
in these PFTs and dyspnea scales could be attributed to treat-
ment of depression and anxiety rather than to any other con-
tributing factors.
Limited studies were done on the assessment of safety and
efﬁcacy of different antidepressants in COPD patients and
used different tools for scoring of depression and anxiety
though only dyspnea scales and/or six or twelve minute walk-
ing distance (6MWD, 12MWD) were used for the assessment
of physiological response to treatment. Our results come in
accordance with the results of Borson and colleagues [23]
who found that treatment of depression resulted in a signiﬁ-
cant improvement in depression and anxiety scores as well as
improved pulmonary function measures (12MWD and dysp-
nea score). Lacasse and colleagues [24] also found that treat-
ment of depression and anxiety resulted in a clinically
signiﬁcant improvement in both depression and anxiety scores
and quality of life. On the other hand, other studies had found
no signiﬁcant difference between patients treated with antide-
pressants and placebo regarding depression and anxiety scores
and pulmonary physiological parameters (either 6MWD or
dyspnea scale) [25–27].
However, it is suggested that improvement in physiological
functions in COPD patients found in our study is not attrib-
uted to the type of antidepressant molecule but to treatment
of depression and anxiety per se as there is no documented
or suggested link between serotonin reuptake inhibition and
COPD improvement, though this may be an issue for further
studies.
Effect of treatment of depression and anxiety 33Several mechanisms may explain the link between depres-
sion and anxiety and functional impairment in patients with
COPD and hence may explain improvement in COPD status
with treatment of depression and anxiety. First, anxiety may
increase disability in COPD by increasing vigilance for, and
ampliﬁcation of, distressing respiratory sensations. The ten-
dency to misinterpret potentially threatening stimuli, a charac-
teristic of many anxiety disorders, would lead anxious COPD
patients to avoid any activity that might produce these sensa-
tions. Second, repetitive experiences with hypoxia and hyper-
capnia in COPD might sensitize neural circuits that control
fear responses, to overreact subsequent episodes of hypoxia
and hypercapnia. These reactions would again lead to avoid-
ance of physical activity and limit exercise performance. Third,
patients with higher anxiety may be more emotionally sensitive
to unpleasant somatic sensations, which would lead to greater
distress even with a normally tolerable level of these symp-
toms. All the mentioned mechanisms create a vicious circle
in which dyspnea leads to anxiety, which produces a rapid
and shallow breathing pattern, leading to air trapping and
hyperinﬂation, creating further dyspnea and exercise limita-
tions [28–30]. Moreover, a concurrent depressive disorder
may bring the patient into a vicious circle: the depressed mood
reduces the patient’s ability to cope with the physical symp-
toms, which become less tolerable. The psychosocial effects
of the disease may be enforced by the inﬂuence of the
depressed mood. Breathlessness on exertion also often leads
to a sense of anxiety further compounding activity avoidance.
This leads to the well-known deconditioning cycle of activity
avoidance [20].
In summary, depression and anxiety have a considerable
role in impairment of the physiological state of COPD patients
and should be thoroughly searched for. Treatment of depres-
sion and anxiety in COPD is recommended as it is associated
with a signiﬁcant improvement in pulmonary physiological
parameters, measured by improvement in pulmonary function
tests and dyspnea scale, besides improvement in quality of life.
Further studies in this issue on larger scales are recommended.
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